Arjan W. Griffioen

CimCure BV is a Dutch new generation company founded in 2015 as a spin-off of the VU University Medical Center. CimCure is based in Amsterdam, Netherlands. The company focuses on the design and development of a novel class of active cancer vaccines that target the tumor blood vessels common to most solid tumors. CimCure has discovered and patented multiple highly specific targets and a novel conjugate vaccine technology that can induce polyclonal antibody responses to targets specific to the tumor vasculature. The company aims to combine the proven efficacy of tumor angiogenesis inhibition with the advantages that a vaccine may provide. The company was founded in 2015 by Arjan W. Griffioen, and Diederik Engbersen has been the CEO of the company since 2020.

SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands.